A subset analysis for quality of life (QoL) was also performed on hemophilia A patients using the Haem-A-QoL questionnaire in patients with hemophilia A. Glycopegylated EHL FVIII therapy significantly reduced ABR and improved joint health and functional scores over 24 months (p<0.001). Here, F8 is linked to hemophilia A.